Several models of GBM organoids can be generated, each offering unique insights: (i) genetically engineered organoids, involving the genetic activation of oncogenes; (ii) patient-derived tumor organoids replicating the tumor microenvironment by including stromal vessels and immune cells; (iii) invasion models, using GSC to invade normal induced pluripotent stem cell (iPSC); (iv) GSC-derived organoids plus Epidermal Growth Factor/Fibroblast Growth Factor (EGF/FGF); and (v) patient-derived GSCs organoids developed without external growth factor supplementation [54]. This evidence concerns the gene EGF and glioblastoma.